The cloning of APP and genetic analysis of families with Alzheimer's disease were both reported in 1987 and much present work on the disease is based upon the foundations laid at that time. Progress was not smooth however, and many errors were made. In this memoir, I lay out both the progress and the errors.
the first to contact us and was numbered "Family 23" simply because letters from 22 others piled on top of it before we answered.
In 1984, Glenner had isolated "beta-amyloid" (now called Aβ) from the meningeal vessels of Alzheimer cases and got a partial sequence (7) . People with Down syndrome nearly always develop Alzheimer's disease (8) and later the same year, Glenner obtained a sequence from a Down's case (9) and, realizing it was the same sequence, wrote in the abstract:
The cerebrovascular amyloid protein from a case of adult Down I regard this as the first implicit statement of the amyloid hypothesis since Glenner clearly thought that overproduction of Aβ leads to Alzheimer's disease.
The following year, Masters and Beyreuther separated and obtained partial sequence of plaque amyloid and realized that it was the same sequence (10) .
With these publications of the sequence, the race was on to clone to amyloid gene. We tried to clone the gene, but unfortunately followed Glenner's view that this was likely to be a blood protein (7) and we spent most of our effort screening cDNA libraries made from human liver. Liver later turned out to be virtually the only tissue not to express the protein. The publication race to clone the gene was won by the Masters and Beyreuther team (11) although in fact a patent had been filed on the gene sequence earlier by Cordell and colleagues (12) . Other groups also cloned the APP gene (13) (14) (15) and all realized that, as Glenner had predicted, its location was on chromosome 21. As this cloning was going on, the first genetic linkage analysis of large Alzheimer families was occurring in the Gusella lab and initial analysis suggested that they showed the Alzheimer locus was also on chromosome 21, close to the centromere (16) and apparently not far from the position of the APP gene (15) . Immediately thereafter, APP gene duplications were reported in a study from France in sporadic Alzheimer's disease (17) .
In fact, it is clear with the benefit of hindsight that in the fevered atmosphere accompanying these observations in 1987, with groups rushing to be the first to make clear findings directly relating APP variants to Alzheimer's disease, a series of errors were made by many groups including ours.
The first error was in the report of the genetic linkage of Alzheimer's disease to the pericentromeric region of chromosome 21 (16) . In fact, the 4 large families used in this report were later shown to have mutations in the presenilin gene on chromosome 14 (18) . The second error related to the report of APP gene duplications (17) and this was quickly determined by a series of negative reports looking for duplications (19) . We (20) and the Gusella lab (21) reported that, in many families there was no evidence for co-segregation of the amyloid gene with Alzheimer's disease. Importantly, the Gusella lab paper used the same families showed complete linkage between disease and the genetic markers at APP. We started to sequence the gene and indeed Christine's lab found the mutation on the day we heard that the Frangione group had already identified APP E693Q as a variant in their single case. Our paper and the Frangione paper describing the mutation and the APP cosegregation were published back to back in Science (24, 25) .
While HCHWA-D and Alzheimer's disease are pathologically and clinically different, clearly the fact that mutations in APP could lead to amyloid deposition was important and this, together with our increasing realization that Alzheimer's disease was genetically heterogeneous (26, 27) started to make our group start to rethink our analytical approach. If the disease was heterogeneous and we wanted to find the gene on chromosome 21, we should only co-analyse those families in which we were sure there was linkage to chromosome 21. There were ostensibly 4 such families, our family F23, FAD4 in which both chromosome 21 linkage and APP exclusion had been reported (15, 16 and 21) and 2 Belgian families in Christine's collection (28) . In FAD4 and in the two Belgian families, the APP gene had been published as being excluded, but in F23, it had not. Over the summer of 1990, our group, Mike Owen, Mike Mullan, Luis Giuffra, Alison Goate and I argued about our own data interpretation and the published data. Eventually we decided to rely only on our own data and to use the newly invented technology of PCR direct sequencing, which Marie Christine Chartier-Harlin had just got to work in our lab, to start to sequencing the APP gene in F23 alone. It worked, and we found the first APP mutation, APP V717I.
Screening all the other families in the lab revealed a second family with the same mutation that Allen Roses had collected (29) . Later the same year, we found a second family with linkage at the APP locus and found the second mutation at the same codon APP V717G (30): a third mutation was found contemporaneously also at the same position (31). We had, therefore, found the first molecularly defined causes of Alzheimer's disease.
I had always thought of genetics as an independent way of testing hypotheses of causation. There had been many competing theories of for Alzheimer's disease and I simply believed that genetics would allow a decision about these competing theories to be made. Genetic analysis told us that amyloid was the cause of Alzheimer's disease in these families, and also in Down syndrome.
Without much thought, I wrote out my verdict on this work first with David
Allsop and then with Gerry Higgins (32, 33) . Contemporaneously Dennis Selkoe came to the same conclusion (34) , and these 3 papers, which Dennis and I have subsequently updated (35, 36) , form the basis for the amyloid hypothesis of the disease. Together these papers have been cited more than 10,000 times.
Subsequently, APP gene duplications were correctly reported to occur in Alzheimer families, also from France (37) . I reviewed this latter paper for Nature Genetics and my only question as a reviewer was to request the authors make sure these families were not in any way related to those in the previous report of French APP gene duplications (17). They were not.
What have I learnt from these events? With regard to experimentation and data analysis the main lesson I have drawn is that if data is critical, make sure you see the raw data yourself. We were misled by the reports that FAD4 and the Belgian families seemed to be chromosome 21 linked but without APP co-segregation (they all later turned out to have presenilin 1 mutations) and this delayed us sequencing our own chromosome 21-linked family (DNA gene sequencing was much more difficult in 1989/1990 than it is now). With regard to expressing my views on pathogenesis: I have always thought it is very important to write what you think clearly. Sometimes you will be wrong, and that is fine, but you should always be clear. A third lesson: given all the mistakes that we and others made in the hotheaded analyses of 1987, is try not to be swept along. Speaking for myself, but also I suspect for the other groups involved in the Nature and Science papers in that year: we were too fast to be careful and, I suspect, the journal editors and reviewers were equally careless. 
